Newsletters

[Pfizer Inc. ] Pfizer Inc., announced that the US FDA has granted full approval to BRAFTOVI^® in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation based on results from the global Phase III BREAKWATER trial.

[Cancer Grand Challenges (Business Wire)] Cancer Grand Challenges, a global initiative co-founded by the National Cancer Institute in the US and Cancer Research UK, announced a major $125m commitment to propel cancer research into uncharted territory.

[Nature Communications] Investigators set out to determine the molecular targets and pathways controlled by Foxl1 during intestinal villification

[Science Advances] Scientists adapted and applied two high-throughput techniques, SNP-STARR-seq and Methyl-STARR-seq, to systematically evaluate the influence of 30,790 noncoding SNPs and more than 134,000 CpG sites on enhancer activity in primary and metastatic CRC cells.

[Cancer Research] Researchers revealed lactylation as a metabolic switch linking cancer glycolytic reprogramming to transcriptional rewiring and proposes targeting PKM2 lactylation to enhance the anti-tumor activity of bevacizumab in colorectal cancer.

[Redox Biology] The authors revealed that p53 induces ferroptosis in the presence of abundant polyunsaturated fatty acids (PUFAs). They uncovered that the availability of PUFAs is crucial for p53 to exert a pro-ferroptotic function in colorectal cancer.

[Science Signaling] Investigators demonstrated that glucose sustained STAT3 activation independently of cytokine availability. Their findings showed how glucose metabolism supports sustained STAT3 activation in colorectal cancer.

[Scientific Reports] Researchers found that knockdown of claudin18.2 (CLDN18.2) inhibited tumor growth in vivo and in vitro. Additionally, CLDN18.2 knockdown down-regulated minichromosome maintenance (MCM) proteins and decreased phosphorylation of ERK, CDK, and MCM2 in gastric cancer cells.

[Biochemistry and Biophysics Reports] Scientists evaluated the effects of the TAAR1 antagonist EPPTB in a DSS-induced colitis model, focusing on inflammation, barrier function, and serotonin signaling, to explore its therapeutic potential.

[Cancer Cell International] Investigators synthesize single-cell RNA sequencing and spatial transcriptomic studies of colorectal cancer to characterize cellular heterogeneity and to delineate spatial niche organization and functional crosstalk within the tumor microenvironment.

[Nature] Ferroptosis resistance of human T cells correlated with plasma lipid profiles across multiple healthy cohorts, exhibiting negative associations with polyunsaturated and monounsaturated fatty acids ratios in major lipid classes.

[Immunological Reviews] The authors integrate human studies with mechanistic models to map convergent pathways that connect pattern-recognition signaling, antigen presentation, and T- and B cell responses with monocyte and macrophage networks that drive injury, fibrosis, and electrical instability.